To evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \[14C\]TAS-205 following oral single doses.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
single oral administration under fasted conditions on day 1
A site selected by Taiho Pharmaceutical Co., Ltd.
Tokyo, Japan
Concentrations of total radioactivity in blood and plasma, plasma TAS-205 concentrations and the pharmacokinetics parameters of TAS-205
Time frame: Day 1 to Day 8
Radioactivity excretion and excretion rate,cumulative excretion, cumulative excretion rate into urine and feces.
Time frame: Day 1 to Day 8
Radioactivity excretion and excretion rate,cumulative excretion, cumulative excretion rate in all excreta (urine and feces).
Time frame: Day 1 to Day 8
Plasma, urinary, and fecal metabolite profiles of TAS-205 , and structural estimation.
Time frame: Day 1 to Day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.